PLRZ.NASDAQPolyrizon LTD

F-1: Polyrizon Ltd. Files for Resale of Over 1.5 Billion Ordinary Shares Following Private Placement

Sentiment:

Registration Statement

📋All filings for Polyrizon LTD
🔒Login to Follow

Polyrizon Ltd. is registering for resale over 1.5 billion ordinary shares by selling shareholders after a recent private placement.

Capital raiseThe company recently completed a private placement, raising approximately $17.0 million.The company may receive additional proceeds from the exercise of warrants issued in the private placement.The company may seek additional capital through a combination of private and public equity offerings, debt financings and collaborations and strategic arrangements.
Worse than expectedThe company has a history of net losses and is a development stage biotech company and has not yet generated revenue from product sales.

Summary

  • Polyrizon Ltd., a development stage biotech company, has filed a registration statement for the resale of up to 1,513,858,167 ordinary shares.
  • These shares consist of (i) 2,245,834 PIPE Shares, (ii) up to 33,170,833 Ordinary Shares issuable upon the exercise of Pre-Funded Warrants, (iii) up to 1,330,897,717 Ordinary Shares issuable upon the exercise of Series A Warrants and (iv) up to 147,543,783 Ordinary Shares issuable upon the exercise of Exchange Warrants.
  • The selling shareholders acquired these shares through a private placement in March 2025.
  • Polyrizon will not receive any proceeds from the sale of these shares by the selling shareholders, but may receive approximately $47.2 million if the warrants are exercised for cash.
  • The company intends to use any proceeds from warrant exercises for general corporate purposes and working capital.
  • Polyrizon is an emerging growth company and a foreign private issuer, which allows for reduced reporting requirements.
  • The company's ordinary shares are listed on the Nasdaq Capital Market under the symbol PLRZ, with the last reported sale price on April 29, 2025, at $0.3070 per share.
  • Polyrizon is developing innovative medical device hydrogels delivered as nasal sprays, targeting viruses and allergens.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has promising technology and recently raised capital, it is still in the development stage and faces significant risks and uncertainties.

Positives

  • The company has a pipeline of product candidates targeting significant market opportunities.
  • The company has a experienced leadership team.
  • The company has a collaboration agreement with Clearmind Medicine Inc. to develop an innovative intranasal formulation aimed at optimizing absorption and therapeutic efficacy of psychedelic-based treatments.
  • The company has secured $17 million in a recent private placement.

Negatives

  • The company is a development stage biotech company and has not yet generated revenue from product sales.
  • The company is dependent on third parties.
  • The company has a history of net losses.
  • The company may not be able to meet the continued listing requirements of Nasdaq.
  • The company's headquarters and other significant operations are located in Israel, and, therefore, its results may be adversely affected by political, economic and military instability in Israel, including the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israels war against them.

Risks

  • The sale of a substantial amount of ordinary shares could adversely affect the prevailing market price.
  • Raising additional capital or the issuance of additional equity securities would cause dilution to existing shareholders.
  • The company may be unable to meet the continued listing requirements of Nasdaq, which could result in delisting.
  • Political, economic, and military instability in Israel could adversely affect the company's business.
  • Clinical trials may not demonstrate safety and efficacy of product candidates.
  • The company may be unable to obtain and maintain regulatory approval of product candidates.

Future Outlook

The company plans to continue developing its product candidates and seek regulatory approvals. The company's success is dependent on securing additional financing and achieving positive clinical trial results.

Industry Context

The company operates in the competitive biotech industry, focusing on nasal drug delivery systems. The company's success will depend on its ability to differentiate its products and secure regulatory approvals.

Comparison to Industry Standards

  • The company is pursuing a 510(k) pathway for PL-14, similar to Alzair, Nasalease and Bentrio.
  • The FDA submission and clearance process took 86 and 140 days, respectively for Alzair, Nasalese and Bentrio.
  • The company is pursuing a De Novo Classification request for PL-15 and PL-16, as there were no potential predicate devices in the FDAs database matching the proposed intended uses of our PL-15 and PL-16 product candidates.

Stakeholder Impact

  • Shareholders may experience dilution from future equity issuances.
  • The company's success will depend on its ability to attract and retain key personnel.
  • The company's product candidates have the potential to improve the health and well-being of patients.

Next Steps

  • Initiate preclinical safety trials for PL-14, PL-15 and PL-16 in the second quarter of 2025.
  • Schedule a pre-submission meeting with the FDA to determine the IDE regulation type of device studies for PL-15 and PL-16 in the second half of 2025.
  • Commence clinical trials for PL-14 between the fourth quarter of 2025 and the first quarter of 2026.
  • Initiate feasibility clinical trials for PL-15 in the third quarter of 2026, subject to securing additional financing.
  • Initiate pivotal clinical trials for PL-15 in the second quarter of 2027, subject to securing additional financing.

Key Dates

DateDescription
January 2005Polyrizon Ltd. incorporated in Israel.
September 29, 2022The Company effected (i) a reverse stock split of our issued and outstanding shares at a ratio of 1-for-8.80, and (ii) cancelled the par value of our Ordinary Shares and Preferred Shares.
December 19, 2022The Company effected the issuance of an aggregate of 858,148 bonus shares to the holders of our Ordinary Shares on a basis of 1.25 bonus shares for each Ordinary Share outstanding (equivalent to a forward share split at a ratio of 1.25-for-1).
June 18, 2023The Company effected a reverse stock split of our issued and outstanding shares at a ratio of 1-for-1.7.
October 7, 2023Hamas terrorists invaded southern Israel and launched thousands of rockets in a widespread terrorist attack on Israel.
May 12, 2024The Company effected a reverse stock split of our issued and outstanding shares at a ratio of 1-for-2.
August 13, 2024We entered into an exclusive patent license agreement with SciSparc Ltd., or the SciSparc License Agreement, pursuant to which we initially issued to SciSparc 320,000 Ordinary Shares.
August 16, 2024The Company effected the issuance of an aggregate of 420,618 bonus shares to the holders of our Ordinary Shares on a basis of 0.1494 bonus shares for each Ordinary Share outstanding (equivalent to a forward share split at a ratio of 0.1494-for-1).
October 2024Israel began limited ground operations against Hezbollah in Lebanon.
November 2024A ceasefire was brokered between Israel and Hezbollah.
December 2024The Assad regime in Syria was overthrown.
March 31, 2025The company entered into a definitive securities purchase agreement with institutional investors for a private placement of approximately $17.0 million.
April 1, 2025The company filed a Report on Form 6-K with the SEC regarding the private placement.
April 8, 2025The company received a notification from Nasdaq that it had 180 days to regain compliance with the minimum bid price requirement.
April 17, 2025Shareholders approved an increase in authorized share capital to 2,000,000,000 ordinary shares.
April 29, 2025The last reported sale price of the company's ordinary shares on Nasdaq was $0.3070 per share.
October 6, 2025Deadline for the company to regain compliance with the Nasdaq minimum bid price requirement.
Second Quarter 2025The company is scheduled to initiate preclinical safety trials for PL-14, PL-15 and PL-16.
Second Half 2025The company intends to schedule a pre-submission meeting with the FDA to determine the IDE regulation type of device studies for PL-15 and PL-16.
Fourth Quarter 2025 First Quarter 2026The company expects clinical trials on its PL-14 product candidate to commence.
Third Quarter 2026The company intends to initiate feasibility clinical trials for PL-15, subject to securing additional financing.
Second Quarter 2027The company intends to initiate pivotal clinical trials for PL-15, subject to securing additional financing.

Keywords

Ordinary Shares, Private Placement, Warrants, Resale, Polyrizon, PLRZ, Biotech, Nasal Spray, Hydrogel, FDA, Clinical Trials, Israel

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.